Evidence map›Paper›PMID 31794523›Full record

ArticleAIDS (London, England)2020

HIV preexposure prophylaxis with tenofovir disoproxil fumarate/emtricitabine and changes in kidney function and tubular health.

Simon B Ascher, Rebecca Scherzer, Michelle M Estrella, Judy Shigenaga, Kimberly A Spaulding, David V Glidden, Megha L Mehrotra, Patricia Defechereux, Monica Gandhi, Robert M Grant and 2 more

Open access · greenAbstract read
In one paragraph

Article in AIDS (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 20 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. The Promise of Tubule Biomarkers in Kidney Disease: A Review.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Review
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 1 country.

Simon B AscherKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco.
Rebecca ScherzerKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco.
Michelle M EstrellaKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco.
Judy ShigenagaKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco.
Kimberly A SpauldingKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco.
David V GliddenDepartment of Biostatistics and Epidemiology.
Megha L MehrotraDepartment of Biostatistics and Epidemiology.
Patricia DefechereuxGladstone Institutes, University of California.
Monica GandhiDivision of HIV, Infectious Diseases, and Global Medicine.
Robert M GrantDivision of Pulmonary and Critical Care Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
Michael G ShlipakKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco.
Vasantha JotwaniKidney Health Research Collaborative, Department of Medicine, San Francisco Veterans Affairs Health Care System and University of California, San Francisco.
San Francisco VA Health Care System · USUniversity of California, San Francisco · USGladstone Institutes · USOffice of Infectious Diseases · US

Funding

LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI Sinead Delany-Moretlwe, RAPHAEL J LANDOVITZ · 2011 to 2026
$779.5M
Virology CoreP30AI027763 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI STEVEN Grant DEEKS · 1988 to 2026
$93.6M
Ujima Mentoring ProgramP30MH062246 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Sheri Ann Lippman · 2001 to 2026
$57.4M
Chemoprophylaxis for HIV Prevention in Men SupplementU01AI064002 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2005 to 2011
$41.3M
The Aging Kidney in HIV-Infection: biomarkers for early detection of injuryR01AG034853 · NIA · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI ESTRELLA, MICHELLE M, SHLIPAK, MICHAEL G · 2010 to 2025
$9.6M
Chemoprophylaxis and HIV-Host InteractionsR01AI062333 · NIAID · J. DAVID GLADSTONE INSTITUTES · PI GRANT, ROBERT M. · 2004 to 2011
$6.2M
Plugging Hair ARV Levels as Adherence Biomarkers into HIV Prevention TrialsR01AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GANDHI, MONICA · 2012 to 2021
$5.6M
Biomarkers of Kidney Injury to Predict AKI Onset and Progression in HIV InfectionR01DK103574 · NIDDK · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI ESTRELLA, MICHELLE M · 2015 to 2020
$3.4M
“Hair Lengthening”: Using Hair Levels to Interpret Long-Acting PrEP Studies.R37AI098472 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Monica Gandhi · 2023 to 2026
$3.2M
Chemoprophylaxis and HIV Host InteractionsR01AI118575 · NIAID · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANT, ROBERT M. · 2015 to 2019
$2.9M
PrEP and ART adherence monitoring using dried blood spotsU01AI106499 · NIAID · UNIVERSITY OF COLORADO DENVER · PI ANDERSON, PETER L. · 2013 to 2016
$2.9M
Biomarkers of Drug-induced Kidney Injury in HIVK23DK109868 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI JOTWANI, VASANTHA KOLAVENNU · 2016 to 2020
$993k
NIAID NIH HHS P30 AI027763NIAID NIH HHS R01 AI062333NIAID NIH HHS R01 AI098472NIAID NIH HHS R01 AI118575NIAID NIH HHS R37 AI098472NIAID NIH HHS U01 AI064002NIAID NIH HHS U01 AI106499NIAID NIH HHS UM1 AI068619NIA NIH HHS R01 AG034853NIDDK NIH HHS K23 DK109868NIDDK NIH HHS R01 DK103574NIMH NIH HHS P30 MH062246
6 · The paper itself

Abstract

objectiveTo evaluate the effects of HIV preexposure prophylaxis (PrEP) with tenofovir disoproxial fumurate (TDF)/emtricitabine (FTC) on kidney function and kidney tubular health.

designThe Iniciativa Profilaxis Pre-Exposicion open-label extension (iPrEx-OLE) study enrolled former PrEP trial participants to receive open-label TDF/FTC. This study included 123 iPrEx-OLE participants who demonstrated PrEP adherence.

methodsWe compared estimated glomerular filtration rate calculated using serum creatinine (eGFRcr), serum cystatin C (eGFRcys), and in combination (eGFRcr-cys), and a panel of 14 urine biomarkers reflecting kidney tubular health before and 6 months after PrEP initiation.

resultsAt baseline, mean eGFRcr, eGFRcys, and eGFRcr-cys were 108.3, 107.0, and 111.1 ml/min per 1.73 m, respectively. Six months after PrEP initiation, eGFRcr declined by -4% (95% CI: -5.7 to -2.4%), eGFRcys declined by -3.3% (95% CI: -8.3 to 1.9%), and eGFRcr-cys declined by -4.1% (95% CI: -7.5 to -0.7%). From the urine biomarker panel, α1-microglobulin and β2-microglobulin increased by 22.7% (95% CI: 11.8--34.7%) and 14.1% (95% CI: -6.1 to 38.6%), whereas chitinase-3-like 1 protein and monocyte chemoattractant protein-1 decreased by -37.7% (95% CI: -53.0 to -17.3%) and -15.6% (95% CI: -31.6 to 4.2%), respectively. Ten of the 14 urine biomarkers, including albumin, had estimated changes of less than 12% with wide confidence intervals.

conclusionSix months of PrEP with TDF/FTC was associated with decreases in eGFRcr and eGFRcys. We also observed for the first time changes in flour of 14 urine biomarkers reflecting kidney tubular health. These findings demonstrate that PrEP has direct effects on eGFR and the proximal tubule.

Indexed as

AdultAgedAnti-HIV AgentsBiomarkersCreatinineCystatin CEmtricitabineFemaleHIV InfectionsHumansKidneyKidney Function TestsKidney GlomerulusLongitudinal StudiesMaleMiddle AgedAnti-HIV AgentsBiomarkersCreatinineCystatin CEmtricitabineTenofovir

Identifiers

PMID31794523
PMCPMC7071971
OpenAlexW2993801515

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.